Technical Analysis for GH - Guardant Health, Inc.

Grade Last Price % Change Price Change
grade A 106.75 0.85% 0.90
GH closed down 1.69 percent on Wednesday, September 23, 2020, on 83 percent of normal volume. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Up
Historical GH trend table...

Date Alert Name Type % Chg
Bearish Engulfing Bearish 0.85%
Upper Bollinger Band Walk Strength 0.85%
Inside Day Range Contraction 0.85%
Overbought Stochastic Strength 0.85%
Upper Bollinger Band Touch Strength 0.85%
New 52 Week Closing High Bullish -0.85%
New 52 Week High Strength -0.85%
Upper Bollinger Band Walk Strength -0.85%
Above Upper BB Strength -0.85%
Overbought Stochastic Strength -0.85%
Older End-of-Day Gignals for GH ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
60 Minute Opening Range Breakdown about 2 hours ago
Down 2 % about 2 hours ago
Up 1% about 3 hours ago
Down 1% about 3 hours ago
Fell Below Previous Day's Low about 3 hours ago
View Earlier Intraday Alerts

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. Its Guardant Health Oncology Platform is designed to leverage its capabilities in technology, clinical development, regulatory and reimbursement to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs. In pursuit of its goal to manage cancer across all stages of the disease, Guardant Health has launched multiple liquid biopsy-based tests, Guardant360 and GuardantOMNI, for advanced stage cancer patients, which fuel its development programs for recurrence and early detection, LUNAR-1 and LUNAR-2, respectively. Since its launch in 2014, Guardant360 has been used by more than 5,000 oncologists, over 40 biopharmaceutical companies and all 27 of the National Comprehensive Cancer Network centers.
Medicine Biopharmaceutical Cancer Disease Oncology Telemedicine Telehealth Precision Medicine

Is GH a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 109.5
52 Week Low 55.9
Average Volume 792,056
200-Day Moving Average 81.90
50-Day Moving Average 90.90
20-Day Moving Average 98.19
10-Day Moving Average 102.32
Average True Range 4.43
ADX 20.38
+DI 27.47
-DI 12.79
Chandelier Exit (Long, 3 ATRs ) 96.22
Chandelier Exit (Short, 3 ATRs ) 100.78
Upper Bollinger Band 108.58
Lower Bollinger Band 87.80
Percent B (%b) 0.87
BandWidth 21.16
MACD Line 4.29
MACD Signal Line 3.52
MACD Histogram 0.7676
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 111.51
Resistance 3 (R3) 112.06 110.73 110.56
Resistance 2 (R2) 110.73 109.29 110.45 110.25
Resistance 1 (R1) 108.29 108.40 107.63 107.74 109.93
Pivot Point 106.96 106.96 106.63 106.68 106.96
Support 1 (S1) 104.52 105.52 103.86 103.97 101.77
Support 2 (S2) 103.19 104.63 102.91 101.45
Support 3 (S3) 100.75 103.19 101.14
Support 4 (S4) 100.20